文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

接种与未接种美国退伍军人感染delta和omicron变异株的不良结局:回顾性队列研究

Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
PubMed 文献 · BMJ · 2023-05-23
一句话结论在近期有医疗使用且多病共存高发的退伍军人中,接种新冠疫苗与感染后30天住院、ICU入住、通气及死亡几率降低相关,且疫苗种类和剂次数与结局显著相关。

该回顾性队列基于美国退伍军人事务部医疗系统,纳入delta期(2021年7月1日至11月30日)95 336例和omicron期(2022年1月1日至6月30日)184 653例首次SARS-CoV-2感染的成人(合并队列平均年龄59.4岁,标准差16.3,87%为男性)。调整人口学和临床特征后,delta期两剂mRNA疫苗相比未接种与住院(aOR 0.41,95%CI 0.39-0.43)、ICU入住(0.33,0.31-0.36)、通气(0.27,0.24-0.30)和死亡(0.21,0.19-0.23)几率降低相关;omicron期两剂mRNA疫苗同样与住院(0.60,0.57-0.63)、ICU(0.57,0.53-0.62)、通气(0.59,0.51-0.67)和死亡(0.43,0.39-0.48)几率降低相关。第三剂mRNA疫苗相比两剂进一步降低所有结局几率:住院(0.65,0.63-0.69)、ICU(0.65,0.59-0.70)、通气(0.70,0.61-0.80)、死亡(0.51,0.46-0.57)。Ad26.COV2.S相比未接种结局更好,但住院和ICU入住几率高于两剂mRNA疫苗;BNT162b2总体结局差于mRNA-1273(aOR 0.97-1.42)。

要点

  • delta期两剂mRNA疫苗相比未接种:住院aOR 0.41(0.39-0.43)、ICU 0.33(0.31-0.36)、通气0.27(0.24-0.30)、死亡0.21(0.19-0.23)。
  • omicron期两剂mRNA疫苗相比未接种:住院aOR 0.60(0.57-0.63)、ICU 0.57(0.53-0.62)、通气0.59(0.51-0.67)、死亡0.43(0.39-0.48)。
  • 第三剂mRNA疫苗相比两剂:住院aOR 0.65(0.63-0.69)、ICU 0.65(0.59-0.70)、通气0.70(0.61-0.80)、死亡0.51(0.46-0.57)。
  • Ad26.COV2.S相比未接种结局更好,但住院和ICU入住几率高于两剂mRNA疫苗。
  • BNT162b2总体结局差于mRNA-1273,调整OR在0.97至1.42之间。

适用人群与场景

  • 美国退伍军人事务部医疗系统附属的成人(≥18岁),在delta期(2021年7月1日至11月30日)或omicron期(2022年1月1日至6月30日)首次确诊SARS-CoV-2感染。
  • 合并队列平均年龄59.4岁(标准差16.3),87%为男性。

诊断标准与关键阈值

  • 首次SARS-CoV-2检测阳性,且处于delta(B.1.617.2)或omicron(B.1.1.529)变异株优势流行期。

研究设计与关键结果

  • 研究类型:回顾性队列;地点:美国退伍军人事务部医疗系统;delta期95 336例感染(47.6%至少接种一剂),omicron期184 653例(72.6%接种)。
  • delta期两剂mRNA疫苗 vs 未接种:住院aOR 0.41(95%CI 0.39-0.43)、ICU入住0.33(0.31-0.36)、通气0.27(0.24-0.30)、死亡0.21(0.19-0.23)。
  • omicron期两剂mRNA疫苗 vs 未接种:住院aOR 0.60(0.57-0.63)、ICU入住0.57(0.53-0.62)、通气0.59(0.51-0.67)、死亡0.43(0.39-0.48)。
  • 第三剂mRNA疫苗 vs 两剂:住院aOR 0.65(0.63-0.69)、ICU入住0.65(0.59-0.70)、通气0.70(0.61-0.80)、死亡0.51(0.46-0.57)。
  • Ad26.COV2.S vs 未接种结局更好,但住院和ICU入住几率高于两剂mRNA疫苗;BNT162b2总体结局差于mRNA-1273(aOR 0.97-1.42)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在近期有医疗使用且多病共存高发的退伍军人中,接种新冠疫苗与感染后30天住院、ICU入住、通气和死亡几率降低相关;疫苗种类和剂次数与结局显著相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine the association between covid-19 vaccination types and doses with adverse outcomes of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during the periods of delta (B.1.617.2) and omicron (B.1.1.529) variant predominance.

DESIGN: Retrospective cohort.

SETTING: US Veterans Affairs healthcare system.

PARTICIPANTS: Adults (≥18 years) who are affiliated to Veterans Affairs with a first documented SARS-CoV-2 infection during the periods of delta (1 July-30 November 2021) or omicron (1 January-30 June 2022) variant predominance. The combined cohorts had a mean age of 59.4 (standard deviation 16.3) and 87% were male.

INTERVENTIONS: Covid-19 vaccination with mRNA vaccines (BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)) and adenovirus vector vaccine (Ad26.COV2.S (Janssen/Johnson & Johnson)).

MAIN OUTCOME MEASURES: Stay in hospital, intensive care unit admission, use of ventilation, and mortality measured 30 days after a positive test result for SARS-CoV-2.

RESULTS: In the delta period, 95 336 patients had infections with 47.6% having at least one vaccine dose, compared with 184 653 patients in the omicron period, with 72.6% vaccinated. After adjustment for patient demographic and clinical characteristics, in the delta period, two doses of the mRNA vaccines were associated with lower odds of hospital admission (adjusted odds ratio 0.41 (95% confidence interval 0.39 to 0.43)), intensive care unit admission (0.33 (0.31 to 0.36)), ventilation (0.27 (0.24 to 0.30)), and death (0.21 (0.19 to 0.23)), compared with no vaccination. In the omicron period, receipt of two mRNA doses were associated with lower odds of hospital admission (0.60 (0.57 to 0.63)), intensive care unit admission (0.57 (0.53 to 0.62)), ventilation (0.59 (0.51 to 0.67)), and death (0.43 (0.39 to 0.48)). Additionally, a third mRNA dose was associated with lower odds of all outcomes compared with two doses: hospital admission (0.65 (0.63 to 0.69)), intensive care unit admission (0.65 (0.59 to 0.70)), ventilation (0.70 (0.61 to 0.80)), and death (0.51 (0.46 to 0.57)). The Ad26.COV2.S vaccination was associated with better outcomes relative to no vaccination, but higher odds of hospital stay and intensive care unit admission than with two mRNA doses. BNT162b2 was generally associated with worse outcomes than mRNA-1273 (adjusted odds ratios between 0.97 and 1.42).

CONCLUSIONS: In veterans with recent healthcare use and high occurrence of multimorbidity, vaccination was robustly associated with lower odds of 30 day morbidity and mortality compared with no vaccination among patients infected with covid-19. The vaccination type and number of doses had a significant association with outcomes.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Bohnert AS, Kumbier K, Rowneki M, et al. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study. BMJ. 2023. PMID: 37220941. doi:10.1136/bmj-2022-074521

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。